Arlington Asset Investment Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAIC research report →
Price Chart
About the company
Arlington Asset Investment Corp. (NYSE: AAIC) functions as a real estate investment trust (REIT), primarily channeling its capital into mortgage-backed instruments and various other assets. The company's principal office is located in the Washington, D.
- CEO
- J. Rock Tonkel Jr., CPA
- IPO
- 1997
- Employees
- 9
- HQ
- Arlington, VA, US
Get TickerSpark's AI analysis on AAIC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $137.08M
- P/E
- 53.78
- PEG
- -0.43
- P/S
- 4.49
- P/B
- 0.64
- EV/EBITDA
- 10.92
- Div Yield
- 0.00%
- Gross Margin
- 80.11%
- Op Margin
- 71.64%
- Net Margin
- 17.77%
- ROE
- 2.46%
- ROIC
- 3.08%
Latest fiscal year · YoY change
- Revenue
- $30.53M+596.4%
- Gross Profit
- $24.46M+551.4%
- Op Income
- $21.87M
- Net Income
- $5.43M+157.0%
- EPS
- $0.09+131.0%
- OCF Growth
- -129.3%
- FCF Growth
- -129.3%
- 52W High
- $4.84
- 52W Low
- $2.53
- 50D MA
- $4.48
- 200D MA
- $3.95
- Beta
- 1.49
- RSI (14)
- 66
- Avg Volume
- 164.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arlington Asset posted a modestly higher book value and positive economic return, while continuing to de-risk through SFR monetization, low leverage, and share repurchases.· November 15, 2022
- Economic return was 2.4% for the quarter, the fifth straight positive quarter, and 8% over the last 12 months.
- Book value rose to $6.45 per share, up 2.4% from the prior quarter end; GAAP net income was $0.10 per share and EAD was $0.11 per share.
- The company sold 371 SFR properties for $130 million gross and $42 million net cash proceeds, booking a $14 million gain and adding $0.47 per share to book value.
- A sale agreement is in place for the remaining 251 SFR properties for $87.3 million gross and about $29 million net cash proceeds, contingent on lender consent and closing conditions.
- MSR and credit investments drove returns, but management signaled no near-term desire to increase Agency MBS exposure and said MSR capital allocation may come down if attractive bids emerge.
Reported third-quarter book value was $6.45 per share, up 2.4% quarter over quarter. GAAP net income was $0.10 per share and earnings available for distribution were $0.11 per share, up $0.06 per share from last quarter. The company generated a 2.4% economic return in the quarter and 8% over the last 12 months. During the quarter, it completed the sale of 371 SFR properties for $130 million gross and $42 million net cash proceeds, realizing a $14 million GAAP gain and contributing $0.47 per share to book value. As of quarter end, overall at-risk leverage was 1.2x, MSR leverage was 0.2x, and MSR investments had $190 million of underlying mortgage servicing rights valued at 5.5x. Looking ahead, the company signed an agreement to sell its remaining 251 SFR properties for $87.3 million gross, expected to produce about $29 million of net cash proceeds and a slight positive book value impact, with closing expected in the fourth quarter. Management described the current environment as one where it will stay in capital preservation mode, keep leverage modest, and continue using share repurchases and opportunistic investments rather than guiding to formal earnings targets.
Rock Tonkel framed the quarter as another example of the firm’s capital-preservation strategy working in a difficult market. He emphasized low leverage, diversified investments, and selective monetization of assets, especially the SFR portfolio, to lock in returns and create liquidity. His tone was constructive and confident, but cautious about near- to intermediate-term housing and broader market volatility.
Rich Konzmann opened with standard forward-looking statement risk language and passed the call to management; the transcript does not include a separate long CFO financial review beyond that. He did provide the reported quarter metrics: book value of $6.45 per share, GAAP net income of $0.10 per share, EAD of $0.11 per share, and at-risk leverage of 1.2x. He also noted the share repurchase authorization remains substantial at 10.2 million shares, or more than $32 million of current market capitalization, and that repurchases have been accretive to book value.
Analysts pressed on share repurchases versus declining liquidity, and management said the multi-year approach of pairing high-return investments with buybacks had worked well, citing roughly 10 million shares repurchased over about two and a half years. Questions on MSR valuation focused on prepayments and multiples; management said the underlying mortgages are nearly 400 basis points out of the money, so cash flows should remain strong, while valuation will depend more on discount-rate moves and broader risk sentiment. On dividends, management said there was no meaningful change in view, though it acknowledged the question is being evaluated alongside capital uses such as buybacks and investment opportunities.
The company is showing consistent positive economic returns while maintaining very low leverage and strong liquidity. Management believes its MSR and high-quality credit positions can continue to generate double-digit returns, and the large remaining buyback authorization gives it another lever to add value if the stock stays depressed.
Management is explicitly stepping away from the SFR strategy for now, and the remaining sale still depends on lender consent and other closing conditions. They also acknowledged that MSR valuations can move with discount rates and risk markets, and that they do not expect to materially increase Agency MBS exposure because capital risk still outweighs carry benefits.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 28.32M
- Float Shares
- 27.03M
of shares held by institutions
2 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AAIC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Militia Capital Partners, LP | 180.66K | ▼ 10.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 14, 23 | Strickler Benjamin J. | other | 29,844 |
| Dec 14, 23 | Strickler Benjamin J. | sell | 121,494 |
| Dec 14, 23 | Konzmann Richard Ernst | other | 801,441 |
| Dec 14, 23 | Konzmann Richard Ernst | other | 611,694 |
| Dec 14, 23 | Konzmann Richard Ernst | other | 28,354 |
| Dec 14, 23 | Konzmann Richard Ernst | sell | 177,306 |
| Dec 14, 23 | Konzmann Richard Ernst | sell | 630,923 |
| Dec 14, 23 | TONKEL J ROCK JR | other | 1,424,782 |
| Dec 14, 23 | TONKEL J ROCK JR | other | 869,280 |
| Dec 14, 23 | TONKEL J ROCK JR | other | 41,273 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AAIC coverage
Recent articles, reports, and earnings notes.
No research on AAIC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AAIC report →Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
globenewswire.com · Jul 15
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
businesswire.com · Jul 15
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
gurufocus.com · Jul 14
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat
gurufocus.com · Jul 14
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
prnewswire.com · Jul 14
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
prnewswire.com · Jul 14
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
gurufocus.com · Jul 14
Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
benzinga.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.